CryoPort (CYRX) Competitors $7.29 -0.37 (-4.83%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYRX vs. EVO, OCUL, SDGR, BHVN, ETNB, ANIP, MESO, EWTX, JANX, and TVTXShould you be buying CryoPort stock or one of its competitors? The main competitors of CryoPort include Evotec (EVO), Ocular Therapeutix (OCUL), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. CryoPort vs. Its Competitors Evotec Ocular Therapeutix Schrodinger Biohaven 89BIO ANI Pharmaceuticals Mesoblast Edgewise Therapeutics Janux Therapeutics Travere Therapeutics Evotec (NASDAQ:EVO) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings. Which has stronger valuation and earnings, EVO or CYRX? CryoPort has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.72-$212.18MN/AN/ACryoPort$228.38M1.60-$114.76M-$2.34-3.12 Is EVO or CYRX more profitable? Evotec has a net margin of -26.34% compared to CryoPort's net margin of -50.15%. CryoPort's return on equity of -11.03% beat Evotec's return on equity.Company Net Margins Return on Equity Return on Assets Evotec-26.34% -21.51% -10.54% CryoPort -50.15%-11.03%-5.54% Do analysts recommend EVO or CYRX? Evotec presently has a consensus target price of $5.93, suggesting a potential upside of 41.95%. CryoPort has a consensus target price of $10.88, suggesting a potential upside of 49.18%. Given CryoPort's stronger consensus rating and higher possible upside, analysts plainly believe CryoPort is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40CryoPort 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders & institutionals hold more shares of EVO or CYRX? 5.8% of Evotec shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 10.1% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, EVO or CYRX? Evotec has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Does the media prefer EVO or CYRX? In the previous week, CryoPort had 3 more articles in the media than Evotec. MarketBeat recorded 4 mentions for CryoPort and 1 mentions for Evotec. Evotec's average media sentiment score of 1.13 beat CryoPort's score of 0.63 indicating that Evotec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCryoPort beats Evotec on 10 of the 14 factors compared between the two stocks. Get CryoPort News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoPortTRANS IndustryTransportation SectorNASDAQ ExchangeMarket Cap$384.05M$5.79B$7.19B$9.03BDividend YieldN/A2.28%914.35%4.07%P/E Ratio-3.1210.5712.8720.03Price / Sales1.601.20320.75108.98Price / CashN/A10.827.5228.59Price / Book0.982.932.095.55Net Income-$114.76M$189.74M$563.51M$248.49M7 Day Performance-2.28%-0.95%2.07%5.37%1 Month Performance4.14%0.80%3.73%6.63%1 Year Performance12.50%-3.42%2.67%21.20% CryoPort Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoPort2.9124 of 5 stars$7.29-4.8%$10.88+49.2%+17.9%$384.05M$228.38M-3.121,186Analyst ForecastGap DownEVOEvotec1.669 of 5 stars$4.20+1.0%$5.93+41.3%-20.8%$1.49B$862.40M0.004,827Positive NewsOCULOcular Therapeutix3.9153 of 5 stars$9.28+0.7%$17.33+86.8%+40.3%$1.48B$59.65M-8.07230Positive NewsSDGRSchrodinger2.7962 of 5 stars$20.12-2.4%$32.80+63.0%+1.2%$1.48B$207.54M-7.65790High Trading VolumeBHVNBiohaven3.1537 of 5 stars$14.11+0.1%$58.46+314.3%-57.1%$1.44BN/A-1.51239ETNB89BIO1.5516 of 5 stars$9.82-0.4%$26.43+169.1%+34.8%$1.43BN/A-2.9140ANIPANI Pharmaceuticals3.6248 of 5 stars$65.25-0.4%$80.13+22.8%+6.3%$1.41B$614.38M-51.38600MESOMesoblast2.1038 of 5 stars$10.89-0.3%$18.00+65.3%+39.4%$1.39B$5.67M0.0080Positive NewsEWTXEdgewise Therapeutics2.6256 of 5 stars$13.11-0.5%$40.00+205.1%-33.3%$1.38BN/A-8.4660JANXJanux Therapeutics1.536 of 5 stars$23.10-0.2%$95.25+312.3%-38.5%$1.37B$10.59M-16.9930TVTXTravere Therapeutics3.148 of 5 stars$14.80+0.2%$32.14+117.2%+90.1%$1.31B$233.18M-5.27460 Related Companies and Tools Related Companies Evotec Competitors Ocular Therapeutix Competitors Schrodinger Competitors Biohaven Competitors 89BIO Competitors ANI Pharmaceuticals Competitors Mesoblast Competitors Edgewise Therapeutics Competitors Janux Therapeutics Competitors Travere Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYRX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CryoPort, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CryoPort With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.